Two Schedules of Teniposide with or Without Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Teniposide
  • Topoisomerase II Inhibitors

abstract

  • The addition of cisplatin to VM26 improves the response rate, progression-free survival interval, and survival duration over VM26 alone, although at the cost of a significant increase in toxicity. Cisplatin should be considered as the basis for combination chemotherapies in advanced NSCLC.

publication date

  • January 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.1996.14.1.127

PubMed ID

  • 8558187

Additional Document Info

start page

  • 127

end page

  • 34

volume

  • 14

number

  • 1